About the Company
We do not have any company description for Trevi Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $TRVI News
Why Trevi Therapeutics (TRVI) Stock Might be a Great Pick
One stock that might be an intriguing choice for investors right now is Trevi Therapeutics, Inc TRVI. This is because this ...
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcript
Trevi Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.1. TRVI isn't one of the ...
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic ...
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
Trevi Therapeutics Inc TRVI
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Trevi Therapeutics Inc (TRVI) Announces Year-End Financials and Progress in Clinical Trials
Warning! GuruFocus has detected 3 Warning Signs with TRVI. On March 20, 2024, Trevi Therapeutics Inc (NASDAQ:TRVI) released its 8-K filing, disclosing its fourth quarter and full-year financial ...
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team
About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of ...
Trevi Therapeutics, Inc. (TRVI) Q4 2023 Earnings Call Transcript
Good afternoon, and welcome to the Trevi Therapeutics Fourth Quarter and Year-End 2023 Earnings Conference Call. At this time, all participants will be in listen-only mode. [Operator Instructions ...
Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
March 20, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for the ...
Loading the latest forecasts...